{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:06:48Z","timestamp":1790089608703,"version":"4.0.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The number of Food and Drug Administration\u2013approved treatments for multiple myeloma (MM), the second most common hematologic malignant neoplasm, has increased substantially over the past 2 decades. Treatment decisions have become more complex over time, and there is variable adoption of new agents in clinical practice. Survival trends have improved with novel therapies; however, these trends are not equitably distributed across patient populations. Although randomized clinical trials have guide treatment strategies, their exclusion of older, medically complex, and socioeconomically disadvantaged patients limits applicability to real-world outcomes. Understanding the natural history of MM and how treatment patterns have changed over time is essential for informing optimal MM care in clinical practice. We retrospectively evaluated 20\u2009135 patients with newly diagnosed MM from the national Veterans Affairs (VA) health system between 2000 and 2024. The VA offers a unique setting to study these patterns in the equal-access context, in which cost is less of a factor, allowing us to assess trends in treatment decisions and outcomes across diverse strata. We analyzed overall survival by treatment regimen, diagnosis era, and sociodemographic features. Lower socioeconomic status as approximated by the area deprivation index was independently associated with increased mortality despite equal health care access. Outcomes continue to improve across treatment eras, although follow-up in the most recent cohort is limited and long-term survival remains incompletely characterized. These findings underscore the need for implementing strategies to address the structural and social barriers to optimal MM care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019843","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:01:42Z","timestamp":1784671302000},"page":"6278-6288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of real-world frontline treatment patterns in multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5790-0767","authenticated-orcid":false,"given":"Alexander","family":"Lazzaro","sequence":"first","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaelyn","family":"Nannini","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenk","family":"Yildirim","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-7610","authenticated-orcid":false,"given":"Linden","family":"Huhmann","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-1053","authenticated-orcid":false,"given":"John M.","family":"Culnan","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June K.","family":"Corrigan","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0454-0173","authenticated-orcid":false,"given":"Danne","family":"Elbers","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"},{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"},{"name":"3Section of Hematology, VA Boston Healthcare System, West Roxbury, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brophy","sequence":"additional","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"},{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"},{"name":"3Section of Hematology, VA Boston Healthcare System, West Roxbury, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"3Section of Hematology, VA Boston Healthcare System, West Roxbury, MA"},{"name":"4Jerome Lipper Multiple Myeloma Center, Division of Plasma Cell Neoplasias, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-3423","authenticated-orcid":false,"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[{"name":"1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA"},{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-0667","authenticated-orcid":false,"given":"Camille V.","family":"Edwards","sequence":"additional","affiliation":[{"name":"2Cooperative Studies Program Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA"},{"name":"5Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"suppl 1","key":"2026092210521117900_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijlh.12360","article-title":"Advances in the pathogenesis and diagnosis of multiple myeloma","volume":"37","author":"Chesi","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"24","key":"2026092210521117900_bib2","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2026092210521117900_bib3","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"26","key":"2026092210521117900_bib4","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2026092210521117900_bib5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2026092210521117900_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/ehm.12.26","article-title":"Role of carfilzomib in the treatment of multiple myeloma","volume":"5","author":"Khan","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2026092210521117900_bib7","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2026092210521117900_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026092210521117900_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"2026092210521117900_bib10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2026092210521117900_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"15","key":"2026092210521117900_bib12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026092210521117900_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"25","key":"2026092210521117900_bib14","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2026092210521117900_bib15","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2026092210521117900_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026092210521117900_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2026092210521117900_bib18","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"2026092210521117900_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16","key":"2026092210521117900_bib20","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2026092210521117900_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1080\/10428194.2020.1767290","article-title":"Treatment disparities in minority groups with multiple myeloma at a safety-net hospital","volume":"61","author":"Dennis","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2026092210521117900_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ajh.23753","article-title":"Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents","volume":"89","author":"Al-Hamadani","year":"2014","journal-title":"Am J Hematol"},{"key":"2026092210521117900_bib23","doi-asserted-by":"crossref","first-page":"103644","DOI":"10.1016\/j.critrevonc.2022.103644","article-title":"Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma","volume":"172","author":"Milrod","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026092210521117900_bib24","doi-asserted-by":"crossref","first-page":"100433","DOI":"10.1016\/j.jcpo.2023.100433","article-title":"Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines","volume":"37","author":"Fahmawi","year":"2023","journal-title":"J Cancer Policy"},{"issue":"5","key":"2026092210521117900_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2026092210521117900_bib26","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3390\/cancers12113488","article-title":"Shaping the treatment paradigm based on the current understanding of the pathobiology of multiple myeloma: an overview","volume":"12","author":"Ninkovic","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026092210521117900_bib27","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2026092210521117900_bib28","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-Medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"2","key":"2026092210521117900_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026092210521117900_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.11213","article-title":"Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study","volume":"97","author":"Advani","year":"2003","journal-title":"Cancer"},{"key":"2026092210521117900_bib31","unstructured":"Veterans Health Administration. Accessed 22 September 2025. https:\/\/www.va.gov\/health\/aboutVHA.asp."},{"issue":"24","key":"2026092210521117900_bib32","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026092210521117900_bib33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/pds.5579","article-title":"Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System","volume":"32","author":"La","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026092210521117900_bib34","doi-asserted-by":"crossref","first-page":"e2300197","DOI":"10.1200\/CCI.23.00197","article-title":"Natural language processing algorithm to extract multiple myeloma stage from oncology notes in the Veterans Affairs Healthcare System","volume":"8","author":"Goryachev","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"7","key":"2026092210521117900_bib35","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969-1998","volume":"93","author":"Singh","year":"2003","journal-title":"Am J Public Health"},{"issue":"11","key":"2026092210521117900_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7326\/M13-2946","article-title":"Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study","volume":"161","author":"Kind","year":"2014","journal-title":"Ann Intern Med"},{"issue":"23","key":"2026092210521117900_bib37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.21105\/joss.00648","article-title":"Comorbidity: an R package for computing comorbidity scores","volume":"3","author":"Gasparini","year":"2018","journal-title":"J Open Source Softw"},{"issue":"1","key":"2026092210521117900_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjsurg.2020.12.001","article-title":"Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high area deprivation index neighborhoods","volume":"222","author":"Mora","year":"2021","journal-title":"Am J Surg"},{"issue":"6","key":"2026092210521117900_bib39","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/hed.27751","article-title":"Higher area deprivation index is associated with poorer local control and overall survival in non-metastatic nasopharyngeal carcinoma","volume":"46","author":"Malik","year":"2024","journal-title":"Head Neck"},{"key":"2026092210521117900_bib40","doi-asserted-by":"crossref","first-page":"102013","DOI":"10.1016\/j.canep.2021.102013","article-title":"Increasing area deprivation index negatively impacts ovarian cancer survival","volume":"74","author":"Hufnagel","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"suppl 1","key":"2026092210521117900_bib41","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1182\/blood-2024-206022","article-title":"Impact of social determinants of health on survival outcomes in multiple myeloma patients at a major cancer center","volume":"144","author":"Abdalla","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026092210521117900_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J Intern Med"},{"issue":"8","key":"2026092210521117900_bib43","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"23","key":"2026092210521117900_bib44","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026092210521117900_bib45","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2023-188272","article-title":"Outcomes of patients with newly diagnosed multiple myeloma experiencing treatment failure after upfront quadruplet therapy and autologous stem cell transplantation","volume":"142","author":"Ravi","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026092210521117900_bib46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1057\/s41285-017-0055-0","article-title":"In BMI we trust: reframing the body mass index as a measure of health","volume":"16","author":"Gutin","year":"2018","journal-title":"Soc Theory Health"},{"issue":"21","key":"2026092210521117900_bib47","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.3390\/cancers14215331","article-title":"Body mass index and overall survival of patients with newly diagnosed multiple myeloma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026092210521117900_bib48","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.clml.2020.11.013","article-title":"Multiple myeloma in Hispanics: incidence, characteristics, survival, results of discovery, and validation using real-world and Connect MM Registry Data","volume":"21","author":"Kaur","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2026092210521117900_bib49","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.1987.5.10.1640","article-title":"The effects of distance from primary treatment centers on survival among patients with multiple myeloma","volume":"5","author":"Lenhard","year":"1987","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026092210521117900_bib50","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2020.05.016","article-title":"Effects of distance from academic cancer center on overall survival of acute myeloid leukemia: retrospective analysis of treated patients","volume":"20","author":"Dhakal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6278\/2589183\/blooda_adv-2026-019843-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6278\/2589183\/blooda_adv-2026-019843-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:23Z","timestamp":1790088743000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6278\/569789\/Evolution-of-real-world-frontline-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019843","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,14]]}}}